Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | -10.42% | -6.74% | +154.40% |
05-08 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+154.40% | 45.74M | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating